Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05864612 · ClinicalTrials.gov registry record · NA
Tools for Anxiety and Depression Screening in Epilepsy
A NA study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- NA
- Development phase
- 880
- Enrollment target
NCT05864612: Completed NA study, sponsored by Wake Forest University Health Sciences.
NCT05864612 is a NA study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 880 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (37% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05864612, a NA study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- NA
- Development phase
- 880 participants
- Enrollment target
Study Summary
A randomized trial to compare patient-completion success of REDCap and Electronic Health Record (EHR)-based anxiety \& depression instrument delivery methods. Study hypothesis is that the screening completion proportion will vary across the 4 modalities tested.
Primary Outcome
Percentage of subjects completing screening instruments by each of the 4 methods prior to clinic visit will be used to compare the effect of the different methods on patient self-completion, and to estimate completion rates by different methods for use in future screening implementation trials.
Interventions
- BEHAVIORAL Screening Questionnaires
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 880 participants |
| Start Date | 2023-09-20 |
| Est. Completion | 2024-09-03 |
| Phase | NA |
What the finished NCT05864612 record still lists
NCT05864612 is an interventional study that assigns participants to a tested intervention. The registered 880 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (37% lower).
The record links to 0 conditions, and to 1 intervention - of which Screening Questionnaires is the first listed.
NCT05864612 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05864612 about?
NCT05864612 is a clinical study titled "Tools for Anxiety and Depression Screening in Epilepsy". A randomized trial to compare patient-completion success of REDCap and Electronic Health Record (EHR)-based anxiety \& depression instrument delivery methods. Study hypothesis is that the screening completion proportion will vary across the 4 modalities tested.
What is the current status of trial NCT05864612?
This trial is currently completed. It is a NA study. The enrollment target is 880 participants. The study started on 2023-09-20. Estimated completion is 2024-09-03.
What interventions are being tested in trial NCT05864612?
The interventions under investigation include: Screening Questionnaires (BEHAVIORAL).
Who is sponsoring clinical trial NCT05864612?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05864612's enrollment target sits among peer trials
880 130th of 2000 higher than 1,871 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05174286 · 880 participants · NA
Community Health Workers United to Reduce Colorectal Cancer and Cardiovascular Disease Among People at Higher Risk
- NCT05454280 · 880 participants · Phase 3
Post-Discharge Risk-Based Management in Patients Undergoing High-Risk Elective Major Cancer Operations (PRS II)
- NCT05525663 · 880 participants · NA
Physical Rehabilitation for Older Patients With Acute Heart Failure With Preserved Ejection Fraction
- NCT06580314 · 880 participants · Phase 3
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI